Maya Abigail Singh

Ms. Maya Abigail Singh

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in The Astrophysical Journal
Verified
Journal Article
Open access
PDF file
JMJames Paul Mason
James Paul Mason
AWAlexandra Werth
Alexandra Werth
CWColin G. West
Colin G. West
AYAllison Youngblood
Allison Youngblood
DWDonald L. Woodraska
Donald L. Woodraska
HLH. J. Lewandowski
H. J. Lewandowski
Flare frequency distributions represent a key approach to addressing one of the largest problems in solar and stellar physics: determining the mechanism that counterintuitively heats coronae to temperatures that are orders of magnitude hotter than the corresponding photospheres. It is widely accepted that the magnetic field is responsible for the heating, but there are two competing mechanisms that could explain it: nanoflares or Alfvén waves. To date, neither can be directly observed. Nanoflares are, by definition, extremely small, but their aggregate energy release could represent a substantial heating mechanism, presuming they are sufficiently abundant. One way to test this presumption is via the flare frequency distribution, which describes how often flares of various energies occur. If the slope of the power law fitting the flare frequency distribution is above a critical threshold, α = 2 as established in prior literature, then there should be a sufficient abundance of nanoflares to explain coronal heating. We performed >600 case studies of solar flares, made possible by an unprecedented number of data analysts via three semesters of an undergraduate physics laboratory course. This allowed us to include two crucial, but nontrivial, analysis methods: preflare baseline subtraction and computation of the flare energy, which requires determining flare start and stop times. We aggregated the results of these analyses into a statistical study to determine that α = 1.63 ± 0.03. This is below the critical threshold, suggesting that Alfvén waves are an important driver of coronal heating.

13 March 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Jared Robert AuclairJared Robert Auclair
Jared Robert Auclair
JJJeewon Joung
Jeewon Joung
MSMaya Abigail Singh
Maya Abigail Singh
GDGael Debauve Debauve
Gael Debauve Debauve
RSRominder SINGH
Rominder SINGH
Cell and Gene Therapy (CGT) represents a paradigm shift in medicine, offering curative potential for previously intractable diseases. However, the complexity, high cost, and manufacturing challenges inherent in developing, producing, and administering these therapies hinder their widespread accessibility. This review examines the critical and increasingly synergistic role of Artificial Intelligence (AI) and Machine Learning (ML) in overcoming these barriers across the entire CGT lifecycle, from discovery and construct design to smart manufacturing, clinical translation, and regulatory applications. We analyze how AI-driven approaches fundamentally differ from conventional methods, facilitating rapid construct optimization, generating highly predictive translational models, enabling the vision of autonomous, digital-twin-driven manufacturing, and establishing new paradigms for pharmacovigilance and regulatory oversight. The integration of AI is not merely an incremental improvement but a foundational transformation, positioning CGT to move from niche, bespoke treatments to scalable, accessible, and highly personalized medical modalities. We conclude by discussing current gaps, particularly data scarcity and regulatory uncertainty, and outlining a roadmap to realize the full potential of AI-enabled CGT.

17 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CBCara Brainerd
Cara Brainerd
MSMaya Abigail Singh
Maya Abigail Singh
JTJohn Tatka
John Tatka
CCCosette Craig
Cosette Craig
SGShane Gilligan-Steinberg
Shane Gilligan-Steinberg
AOAyokunle Olanrewaju
Ayokunle Olanrewaju
Maintaining adequate levels of antiretroviral (ARV) medications is crucial for the efficacy of HIV treatment and prevention regimens. Monitoring ARV levels can predict or prevent adverse health outcomes like treatment failure or drug resistance. However, conventional ARV measurement using liquid chromatography-tandem mass spectrometry (LC-MS/MS) is slow, expensive, and centralized delaying clinical and behavioral interventions. We previously developed a rapid enzymatic assay for measuring nucleotide reverse transcriptase inhibitors (NRTIs) — the backbone of HIV treatment and prevention regimens — based on the drugs' termination of DNA synthesis by HIV reverse transcriptase (RT) enzyme. Here we expand our work to include non-nucleoside reverse transcriptase inhibitors (NNRTIs) — an ARV class used in established and emerging HIV treatment and prevention regimens. We demonstrate that the REverse Transcriptase ACTivity (REACT) assay can detect NNRTIs including medications used in oral and long-acting/extended-release HIV treatment and prevention. We demonstrate that REACT can measure NNRTIs spiked in either buffer or diluted plasma, and that fluorescence can be measured on both a traditional plate reader and an inexpensive portable reader that can be deployed in point-of-care (POC) settings. REACT measured clinically relevant concentrations of five NNRTI spiked in aqueous buffer. REACT measurements showed excellent agreement between the plate reader and the portable reader, with a high correlation in both aqueous buffer (Pearson's r=0.9807, P < 0.0001) and diluted plasma (Pearson's r = 0.9681, P < 0.0001). REACT has the potential to provide rapid measurement of NNRTIs in POC settings and may help to improve HIV treatment and prevention outcomes.

28 October 2024 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
CBCara Brainerd
Cara Brainerd
MSMaya Abigail Singh
Maya Abigail Singh
JTJohn Tatka
John Tatka
CCCosette Craig
Cosette Craig
SGShane Gilligan-Steinberg
Shane Gilligan-Steinberg
AOAyokunle Olanrewaju
Ayokunle Olanrewaju

11 February 2025 in ACS Synthetic Biology
Verified
Journal Article
Open access
MSMaya Abigail Singh
Maya Abigail Singh
MCMegan M. Chang
Megan M. Chang
QWQin Wang
Qin Wang
CRCatherine Rodgers
Catherine Rodgers
BLBarry Lutz
Barry Lutz
AOAyokunle Olanrewaju
Ayokunle Olanrewaju
Maintaining the efficacy of human immunodeficiency virus (HIV) medications is challenging among children because of dosing difficulties, the limited number of approved drugs, and low rates of medication adherence. Drug level feedback (DLF) can support dose optimization and timely interventions to prevent treatment failure, but current tests are heavily instrumented and centralized. We developed the REverse transcriptase ACTivity crispR (REACTR) for rapid measurement of HIV drugs based on the extent of DNA synthesis by HIV reverse transcriptase. CRISPR-Cas enzymes bind to the synthesized DNA, triggering collateral cleavage of quenched reporters and generating fluorescence. We measured azidothymidine triphosphate (AZT-TP), a key drug in pediatric HIV treatment, and investigated the impact of assay time and DNA template length on REACTR's sensitivity. REACTR selectively measured clinically relevant AZT-TP concentrations in the presence of genomic DNA and peripheral blood mononuclear cell lysate. REACTR has the potential to enable rapid point-of-care HIV DLF to improve pediatric HIV care.

28 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMaya Abigail Singh
Maya Abigail Singh
MCMegan M. Chang
Megan M. Chang
QWQin Wang
Qin Wang
CRCatherine Rodgers
Catherine Rodgers
BLBarry Lutz
Barry Lutz
AOAyokunle Olanrewaju
Ayokunle Olanrewaju
Maintaining efficacy of human immunodeficiency virus (HIV) medications is challenging among children because of dosing difficulties, the limited number of approved drugs, and low rates of medication adherence. Drug level feedback (DLF) can support dose optimization and timely interventions to prevent treatment failure, but current tests are heavily instrumented and centralized. We developed the REverse-transcriptase ACTivity-crispR (REACTR) assay for rapid measurement of HIV drugs based on the extent of DNA synthesis by HIV reverse transcriptase. CRISPR-Cas enzymes bind to synthesized DNA, triggering collateral cleavage of quenched reporters and generating fluorescence. We measured azidothymidine triphosphate (AZT-TP), a key drug in pediatric HIV treatment, and investigated the impact of assay time and DNA template length on REACTR’s sensitivity. REACTR selectively measured clinically relevant AZT-TP concentrations in the presence of genomic DNA and peripheral blood mononuclear cell lysate. REACTR has the potential to enable rapid point-of-care HIV DLF to improve pediatric HIV care.